



STIC Search Report

Biotech-Chem Library

STIC Database Tracking

TO: Anne Holleran
Location: o 8E03; m 8E12
Art Unit: 1642
Tuesday, July 08, 2003
Case Serial Number: 09/822295

From: Barb O'Bryen
Location: Biotech-Chem Library
CM1-6A05
Phone: 308-4291
barbara.obryen@uspto.gov

Search Notes



PI Markby D., Ernst S., Peles E., Plowman GD;
 DR WPI: 1999-009434/01.
 XX
 XX New nucleic acid encoding specific protein tyrosine phosphatases
 PT useful for identifying specific modulators for treatment and
 PT prevention of cancer and neurodegenerative disease
 XX
 XX Example 4; Page 81; 199pp; English.
 PS
 XX The present invention describes isolated, enriched or purified nucleic
 CC acids encoding ptp04, SAB, ptp05, ptp10, A-P and ALK-7 proteins. The
 CC above proteins, other than ALK-7, are protein tyrosine phosphatases
 CC (PTPs) and are used to identify substances that modulate their activity
 CC (i.e., agonists and antagonists), including WBP, in vivo or in vitro.
 CC These substances are used to treat or prevent diseases associated with
 CC abnormal signal transduction pathways that involve the proteins,
 CC particularly cancer (e.g., leukemia and lymphoma), while modulators of
 CC ALK-7 (which is a type I receptor serine/threonine kinase) are used to
 CC promote neuronal survival, particularly for treating Alzheimer's,
 CC Parkinson's or Huntington's diseases. Nucleic acid fragments of the
 CC polynucleotides encoding the proteins can be used as probes to identify
 CC and clone related sequences; to detect protein-encoded RNA; to generate
 CC transgenic animals and in gene therapy (optionally after mutation). Ab
 CC are used to determine the proteins. The present sequence represents a
 CC human ptp04 peptide from the present invention.
 XX
 SQ Sequence 31 AA;
 Query Match 100.0%; Score 165; DB 20; Length 31;
 Best Local Similarity 100.0%; Prod. No. 1,96-17;
 Matches 31; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 SWPPSCTSSKMSLDLPEKQGVTPSSLLP 31
 DB 1 SWPPSCTSSKMSLDLPEKQGVTPSSLLP 31
 RESULT 2
 AAY28654
 ID AAY28654 standard; Protein: 692 AA.
 AC AAY28654;
 XX
 XX 01-001 1999 (first entry)
 DT Human cytoplasmic phosphatase, Lyp2 protein.
 DE
 XX Lymphoid protein tyrosine phosphatase; Lyp protein; immunosuppressant;
 KW intracellular tyrosine phosphatase; pipase, fetal liver; transplant;
 KW resting lymphoid cell; protein tyrosine kinase; ptp; lymphocyte;
 KW T cell antigen receptor signalling; cytokine receptor signalling;
 KW autoimmune disease; intronic sequence; alternative mRNA splicing.
 XX
 OS Homo sapiens.
 XX
 XX Key localization/Qualifiers
 FH Domain 27..289
 FT /label= ptpase domain
 FT /note= "Single catalytic protein tyrosine phosphatase
 FT domain"
 FT Domain 469..472
 FT /label= NXY_motif
 FT /note= "motif sequence recognised by phosphotyrosine
 FT binding (PTB) domain"
 FT Binding site 615..623
 FT /label= SH2 binding site
 FT /note= "positive regulatory sequence"
 XX
 XX W09946548-A1.
 PN
 XX 22-101-1999.
 PD
 XX

DE 18 JAN 1999; 99w; CA000000.
 XX
 XX 16 JAN 1999; 99w; CA000000.
 XX
 XX (HSCR) HSC FES & FIV LP.
 PA
 XX Rottman CW;
 FI
 XX WPI: 1999-44474/01.
 DR N PSDB; AAX90560.
 XX
 XX New nucleic acid encoding intracellular tyrosine phosphatases and
 PT related proteins, used to modulate signalling for cancer therapy,
 PT particularly as immunosuppressant
 XX
 XX Claim 4b; Page 55; 106pp; English.
 PS
 XX The present protein sequence is that of the cytochrome b5 domain
 CC protein tyrosine phosphatase, Lyp2 protein, that has a kinase domain
 CC domain. The non-catalytic portion of the phosphatase is of unknown
 CC sequence, including a single PEST sequence (residues 1-100). A
 CC and Thr. It is expressed specifically in fetal liver and in resting
 CC lymphoid cells. Lyp2 is an isoform of the Lyp protein that displays
 CC alternative splicing of the mRNA. The intronic region of the exon
 CC for the C-terminal 7 amino acids and part of the 3' untranslated region
 CC Lyp2. Lyp2 shares sequence identity with the nuclear phosphatase
 CC Lyp1. Lyp proteins are important for regulation of cell cycle and
 CC receptor signalling and for early and late stages of T cell
 CC differentiation. Lyp2 has immunosuppressive activity and can
 CC increase expression of Lyp protein can be used as an immunosuppressant
 CC agents to reduce or prevent T cell activation or proliferation in
 CC control thymocyte differentiation, to treat and modulate cancer and
 CC transplant situations.
 XX
 SQ Sequence 692 AA;
 Query Match 90.0%; Score 146.5; DB 20; Length 692;
 Best Local Similarity 90.0%; Prod. No. 199-199;
 Matches 40; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 SWPPSCTSSKMSLDLPEKQGVTPSSLLP 41
 DB 640 SWPPSCTSSKMSLDLPEKQGVTPSSLLP 640
 RESULT 3
 AAY378624
 ID AAY378624 standard; Protein: 799 AA.
 AC AAY378624;
 XX
 XX 04-100 2001 (first entry)
 FI
 XX Human tyrosine phosphatase.
 DE
 XX Human tyrosine phosphatase; LYP.
 KW
 XX Homo sapiens.
 OS
 XX ENSG02899 A.
 XX 11-101-2001.
 PP
 XX 29 OCT 1999; 99N 0119900.
 XX
 XX 29 OCT 1999; 99N 0119900.
 XX
 XX (AAY) 3 AAY378624; HSC FES & FIV LP; HUMAN
 XX
 XX Rottman CW; WPI: 1999-44474/01.
 FI
 XX WPI: 2001-44474/01.
 DR N PSDB; AAX90560.
 XX

XX human protein tyrosine phosphatase and its coding sequence -
 XX class 4: Page 12 14 (disclosure) - 29pp; Chinese.
 XX The present invention provides the protein and coding sequences of human
 CC tyrosine phosphatase hpp. The protein is expressed in human normal
 CC supranatural tissue. The present sequence is the protein of the invention.
 XX
 SQ Sequence 700 AA:

Query Match
 Best Local Similarity 90.08% Score 148.5; DB 22; Length 799;
 Matches 40; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 SWPSSGSSSSSLGLPQKQGVTFSSSLP 51
 DB 534 SWPSSGSSSSSLGLPQKQGVTFSSSLP 500

RESULT 4
 AAW89247
 ID AAW89247 standard; Protein: 80 AA.
 AC AAW89247;
 XX

DI 01-MAY-1999 (first entry)
 DE Human PTP04.

XX PTP04; PTP05; PTP10; SAD; ALP; ALK-7; protein tyrosine phosphatase;
 KW type I receptor serine/threonine kinase; cancer; leukaemia; lymphoma;
 KW neurodegenerative disease; neuronal survival; Alzheimer's disease;
 KW Parkinson's disease; Huntington's disease.
 XX

OS Homo sapiens.

XX W0949337-A2.
 FN 05-NOV-1998.
 XX

DI 23 APR-1998; 9806-0508439.
 XX

PR 24 OCT-1997; 9708-0064595.
 PR 24 APR-1997; 9708-0044428.
 PR 20 APR-1997; 9708-0047222.
 PR 11 JUN-1997; 9708-0045477.
 PR 11 JUN-1997; 9708-0049755.
 PR 18 JUN-1997; 9708-0049914.
 XX

PA (SUGEN) SUGEN INC.
 XX

PI App B; Clary D; Courtice SA; Hui RH; Jallat B;
 PI Markby D; Onrust S; Peles E; Plowman GD;
 XX

DI W01; 1999-00943470.
 DI N DSUB; AAW81742.
 XX

XX New nucleic acid encoding specific protein tyrosine phosphatases -
 PT useful for identifying and specific inhibitors for treatment and
 PT prevention of cancer and neurodegenerative disease
 XX

FS claim 2: Page 151-153; 19pp; English.
 XX

XX The present invention describes isolated, enriched or purified nucleic
 CC acids encoding PTP04, SAD, PTP05, PTP10, ALP and ALK-7 proteins. The
 CC present sequence represents human ptp04. The above proteins, other than
 CC ALK-7, are protein tyrosine phosphatases (PTPs) and are used to identify
 CC substances that modulate their activity (i.e. agonists and antagonists,
 CC including NBP) in vivo or in vitro. These substances are used to treat
 CC or prevent diseases associated with abnormal signal transduction
 CC pathways that involve the proteins, particularly cancer (e.g. leukaemia
 CC and lymphoma), while modulators of ALK-7 (which is a type I receptor

CC serine/threonine kinase) are used to promote neuronal survival
 CC particularly for treating Alzheimer's, Parkinson's, Huntington's
 CC diseases. Nucleic acid fragments of the polynucleotides encoded in the
 CC proteins can be used as probes to identify and clone related sequences
 CC to detect protein-encoded RNA; to detect transcribed RNAs and to
 CC gene therapy (optionally after mutation). All are good candidates for
 CC proteins.
 XX

SQ Sequence 907 AA:

Query Match
 Best Local Similarity 90.08% Score 148.5; DB 22; Length 799;
 Matches 40; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

QY 1 SWPSSGSSSSSLGLPQKQGVTFSSSLP 51
 DB 534 SWPSSGSSSSSLGLPQKQGVTFSSSLP 500

RESULT 5
 AAY28652

IT AAY28652 standard; Protein: 808 AA.
 XX

AC AAY28652;
 XX

DI 01-OCT-1995 (first entry)
 DE Human Cytosolic phosphatase, typl protein.

XX Lymphoid Protein Tyrosine Phosphatase, Lyp protein, lymphoid
 KW intracellular tyrosine phosphatase; protein; lymphocyte; thymocyte;
 KW T cell; B cell; protein tyrosine kinase; kinase; immunosuppressant;
 KW T cell antigen receptor signalling; cytokine receptor signalling;
 KW autoimmune disease; transplant.
 XX

OS Homo sapiens.

XX Key
 XX Domain
 XX

FT 27..289
 FT /label= ptpase_domain
 FT /note= "Single catalytic protein tyrosine phosphatase
 FT domain"

FT 469..472
 FT /label= NXXY_motif
 FT /note= "Unique sequence recognised by phosphotyrosine
 FT binding (PTB) domain"

FT 645..623
 FT Binding_size
 FT

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 694..701
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 702..736
 FT Region

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 741..745
 FT Region

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 766..772
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 796..804
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 809..815
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 816..822
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 823..829
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 830..836
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 837..843
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 844..850
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 851..857
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 858..864
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 865..871
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 872..878
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 879..885
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 886..892
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 893..899
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 899..905
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 906..912
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 913..919
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 920..926
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 927..933
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 934..940
 FT Binding_size

FT /label= SH3_binding_site
 FT /note= "Proline rich sequence"
 FT 941..947
 FT Binding_size

1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000
---	---	---	---	---	---	---	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------

[illegible]

(c) Immunohisto stains expression ((1)) and ((1)) are useful for treatment disorders involving aberrant protein expression or those for activity.

(d) The polypeptide and polynucleotide sequences have applications in:

(e) diagnostics; forensics; gene mapping; identification of mutations responsible for genetic disorders; or other efforts to assess health status;

(f) to produce other types of drugs and products dependent on RNA and amino acid sequences; Ab060470-Ab060487 represent novel human diagnostic antibody acid sequences of the invention;

(g) Metastatic cancer data for this patent did not appear in the Human Specimen Bank, but was obtained if electronic format directly from WHO at ftp://ftp.ncbi.nih.gov/pub/fdb/human_97_sequences.

XX Sequence 195 AA;
XX
XX Query March 31, 2001 Score 14.7 E -16 Length 195
XX Local Similarity 47.9%; Posit Neg %
Matches 11; Conservative 4; Mismatches 11; Indels 4 Gaps

XX 2 WPGSTSSKMSLIDHGR KQVIVESEGL QG
XX III I I I II I I I I
XX 116 WTFFSRLTKAKMDETR DEWYRILIM LLI

BLAST 1.3
Ab0646.vr
XX 1) Ab0646.vr standard; Protein 195 AA
XX At Ab0646.vr;
XX 22 MAR 2001 (first entry)

XX human secreted protein BLAST search results file; ID No: 147.
XX
XX C/I search; Image sequence; query length 195 aa; and target
XX database; RefSeqRefseq and UniProtKB; and identifier
XX nomenclature; accession number; and internal annotations; e.g.,
XX candidate; gene therapy; cancer; immune disorder cardiovascular disorder
XX neurological disorder; infection; human; secreted proteins.

XX Homo sapiens.
XX
XX W02007197-A1.
XX
XX 21-DIC-2000.
XX
XX 01-JUN-2000; 2000WD-US149 v4.
XX
XX 11 JUN 1999. 93DS 0185509.
XX
XX (HUMA-) HUMAN CHROMO SGT INC.
XX (USP) ROSEN C A.
XX
XX Rosen CA, Rubin SM, Komatsoulis EA
XX WPt: 2001-032412/04.
XX
XX Isolated nucleic acid molecule encoding a human secreted protein as
XX used in preventing, treating or diagnosing a disease, especially a
XX
XX Disclosure Page 544-544; 554bp; Identical.

XX The invention relates to the isolation of genes AB0646.vr - cDNA clones
XX the human secreted proteins Ab0646.vr p646v4. The sequence is a stretch
XX result from a BLASTX homology search. The above and proteins are used in:
XX prevention, ameliorating or providing medical conditions, e.g., by
XX protein or gene therapy. The genes are isolated from a range of human
XX tissues disclosed in the specification. In the nucleic acids, proteins,
XX antibodies and conjugates are acting in the diagnosis, treatment
XX and prevention of: (a) cancer, e.g. breast and colon cancer, and
XX other cancers of the adrenal gland, bone, bone marrow, breast,
XX gastrointestinal tract, liver, lung or prostate; (b) autoimmune
XX disorders e.g. Addison's disease, Graves' disease, autoimmune haemolytic
XX anaemia, autoimmune thyroiditis, diabetes mellitus, chronic disease,

W: 1000 1000/10.

Now isolated human genes and the secreted polypeptides they encode -
 useful for diagnosis and treatment of e.g. cancers, neurological
 (auto)immune diseases, inflammation or blood disorders

(translation frame 105: 4149): English.

This sequence represents a fragment of a secreted human protein encoded
 by the above described molecule detailed in the descriptor line. The gene
 can be used to generate fusion proteins by linking to the gene to a
 human immunoglobulin Fc portion (e.g. AAX27302) for increasing the
 stability of the fused protein as compared to the human protein only.
 The fusion protein relates to 23 novel genes and their fragments (nucleic
 acid sequences: AAX27311-A27344; amino acid sequences: AAV02650-Y02788)
 which are useful for preventing, treating or ameliorating medical
 conditions caused by protein or gene therapy. Also, pathological
 conditions can be diagnosed by determining the amount of the new
 polypeptides in a sample or by determining the presence of mutations in
 the new polypeptides. Specific uses are described for each of the 23
 polypeptides, based on which tissues they are most highly expressed in
 (see AAX27311 for described uses).

Seq: 50 protein: 17 AAX

GenBank: M10000 4189: Score 52.5; DB 20; Length 57;
 Description: SECRETED PROTEIN; 60,0%; Prot. No. 2.5;
 M10000: 17: 100% identical; 0: Mismatches 7; Indels 1; Gaps 1;

50 1 SWISSPROT SUBMITTER 19
 11 11 11 11 11
 14 46 SWISSPROT APPENDIX 55

Search completed: July 8, 2003, 12:09:46
 Job time: 1:52:31h secs



1 NAME: [REDACTED] 2 ADDRESS: [REDACTED] 3 CITY: [REDACTED] 4 STATE: [REDACTED] 5 ZIP: [REDACTED] 6 PHONE: [REDACTED] 7 FAX: [REDACTED] 8 E-MAIL: [REDACTED] 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

1 NUMBER OF SEQUENCES: 18 2 CYRSPONSE: ADDRESS: 3 ADDRESS: 1906 S Lyon 4 STREET: 644 West Fifth Street 5 STREET: Suite 4700 6 CITY: Los Angeles 7 STATE: California 8 COUNTRY: U.S.A. 9 ZIP: 90071-2066 10 11 COMPUTER READABLE FORM: 12 RICH TYPE: 1.00 13 RICH TYPE: 1.44 MB 14 MEDIUM TYPE: Standard 15 COMPUTER: IBM compatible 16 OPERATING SYSTEM: IBM PC, DOS 5.0 17 SOFTWARE: FASTSPD, LOT Windows 2.0 18 CURRENT APPLICATION DATA: 19 APPLICATION NUMBER: 05/07/081,445 20 FILING DATE: Herewith 21 CLASSIFICATION: 22 PRIOR APPLICATION DATA: 23 APPLICATION NUMBER: 60/047,222 24 FILING DATE: May 20, 1997 25 ALTERNATE/OTHER INFORMATION: 26 NAME: WATSON, Richard J. 27 REGISTRATION NUMBER: 92,427 28 RETIREMENT/RECALL NUMBER: 92,427 29 TELEPHONE: (213) 489-1604 30 TELEFAX: (213) 955-0440 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

1 US-09-081-445-1B

1 Query Match 53.6% Score 88.5% DB 4 Length 602 2 Host Local Similarity 61.4% Prod. No. 2-20-05 3 Matches 19 Conserved 19 Mismatches 99 Indels 1 Gaps 1

1 US-09-069-024-41

1 Sequence ID: Application US/069-024-41 2 Patent No. 6448574 3 GENE: INFORMATION 4 APPLICANT: Nitro, Gabriel 5 APPLICANT: Nitro, Gabriel 6 APPLICANT: KOSKI, Takayoshi 7 TITLE OF INVENTION: COMBINATIONS AND METHODS FOR THERAPY AND DIAGNOSIS 8 FILE REFERENCE: 06/04444 9 CURRENT APPLICATION NUMBER: US-09-069-024-41 10 FILING DATE: 1998-04-27 11 NUMBER OF SEQ. IN SEQ: 48 12 SOFTWARE: Patent In Vol. 2.0 13 SEQ ID NO 41 14 LENGTH: 239 15 TYPE: PRT 16 ORGANISM: Mus musculus 17 US-09-069-024-41

1 Query Match 42.1% Score 53.1 DB 4 Length 602 2 Host Local Similarity 53.6% Prod. No. 1-5 3 Matches 15 Conserved 15 Mismatches 109 Indels 2 Gaps 1

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

```

Sequence 1 Application US/0942787A
Patent No. 617659
GENERAL INFORMATION
APPLICANT ASHLEY, Gary
APPLICANT BELLACH, Mariano C.
APPLICANT BETLACH, Mary O.
APPLICANT MCGANIEH, Robert
APPLICANT TANG, Li
TITLE OF INVENTION: ACRYLIC POLYMER NANOBLENDED LAYERED LAMINATE
FILE REFERENCE: 200622002120
CURRENT FILING DATE: 1999-05-27
PREVIOUS APPLICATION NUMBER: 09/07141, 90B
EARLIER FILING DATE: 1998-08-28
EARLIER APPLICATION NUMBER: GIP OF 09/073, 548
EARLIER FILING DATE: 1998-05-06
EARLIER APPLICATION NUMBER: GIP OF 08/846, 247
EARLIER FILING DATE: 1997-04-30
EARLIER APPLICATION NUMBER: 60/7119, 189
EARLIER FILING DATE: 1999-02-08
EARLIER APPLICATION NUMBER: 60/7100, 880
EARLIER FILING DATE: 1998-09-22
EARLIER APPLICATION NUMBER: 60/087, 080
EARLIER FILING DATE: 1998-05-28
NUMBER OF SEQ. IN NO. 34
SOFTWARE: Patented Ver. 2.0
SEQ ID NO 1
LENGTH: 4552
TYPE: PRT
ORIGIN: STRATAGEMES VENTURES INC
US 09 420 878-1

Query Match
Score: 49.5% DB: 3 Length: 4551
Best Local Similarity: 47.6% Prod. No.: 2.6e+02
Matches: 10; Conservative: 4; Mismatches: 6; Indels: 1; Gaps: 1

2 WPPSSSKMSLSIDLPKQDQ 22
|||||.....||..||..||..|
3660 WPPSSKMSLSIDLPKQDQ 3679

RESULT 10
US 09 105 537-41
SEQUENCE 11 Application US/0941057A
Patent No. 6269202
GENERAL INFORMATION
APPLICANT Sherman, D.H.
APPLICANT Liu, H.
APPLICANT Xue, Y.
APPLICANT Zhao, L.
TITLE OF INVENTION: DNA encoding methymycin and pikromycin
FILE REFERENCE: 600,438051
CURRENT APPLICATION NUMBER: US/09/105, 537A
NUMBER OF SEQ. IN NO. 45
SOFTWARE: FASTSeq for Windows Version 8.0
SEQ ID NO 41
LENGTH: 4613
TYPE: PRT
ORIGIN: STRATAGEMES VENTURES INC
US 09 105 537-41

Query Match
Score: 49.5% DB: 3 Length: 4613
Best Local Similarity: 47.6% Prod. No.: 2.6e+02
Matches: 10; Conservative: 4; Mismatches: 6; Indels: 1; Gaps: 1

2 WPPSSSKMSLSIDLPKQDQ 22
|||||.....||..||..||..|
3672 WPPSSKMSLSIDLPKQDQ 3741

```


LENGTH: 31 amino acids

LEITE, INGRAM, & N. KADANAGA Study of the naturally occurring L-amino acids

US-10-128-714-3058

CURRENT APPLICATION NUMBER: 10182-018-994

```

1 CURRENT APPLICATION NUMBER: 002100128,714
2
3 CURRENT FILING DATE: 2002 01 21

```


1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

UN KAU470 OR SMA0561.
US Rhizobium meliloti (Sindorbicobium meliloti).
OC plasmid pSymA (metaplasmid 1).

to restore normal activity of (11) or to treat disease states involving (11). (11) is useful for generating antibodies against it, detecting or identifying a polypeptide in tissue, as molecular weight markers and as a food supplement. (11) and its binding partners are useful in medical testing of stress expression (11). (1) and (11) are useful for treating the polypeptide and polynucleotide sequences have applications in diagnostics, forensics, gene mapping, identification of mutations in response to genetic disorders or other traits to assess diversity and to provide other types of data and products dependent on DNA and amino acid sequences. Ab000010-Ab030377 represent novel human fibronectin amino acid sequences of the invention.

Note: The sequence data for this patent did not appear in the printed specification, but was obtained in electronic format directly from WIPO at http://wipo.int/pub/published_fet_sequences.

XX Sequence: 222 AA:

Query Match: 24.8%; Score 48; DB 22; Length 222;

Best Local Similarity: 45.2%; Pred. No. 32;

Motif: 14; Conservative: 2; Mismatches: 11; Indels: 4; Gaps: 2;

QV 11VRSK-HQIRNASNKH-HDSALGVYS 29

111 11 11 111111

14 11VRSNRYHAFVASTARHIVPNSALGVCS 122

Status: Complete: July 8, 2003 12:09:47
 to file: 13:54:00:00



Software version 5.0.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

M Protein: Protein search, using sw model

Run date: July 8, 2003, 12:08:17 ; Search time 14,5055 Seconds
(without alignments)

60 852 Million cell updates/sec

111,000 MS-09-822-295-16

1,531,436,822,295-16

1,531,436,822,295-16

Search time: 14,5055 Seconds

26,2574 seqs, 264,229,222 residues

26,2574

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

Maximum number of hits satisfying chosen parameters:

ALIGNMENTS

28	43	25.7	292	4	US-09-176-666-4	Sequence 4, Appl1
29	43	25.7	304	4	US-09-176-666-4	Sequence 4, Appl1
30	43	25.7	306	4	US-09-176-666-4	Sequence 4, Appl1
31	43	25.7	308	4	US-09-176-666-4	Sequence 4, Appl1
32	43	25.7	310	4	US-09-176-666-4	Sequence 4, Appl1
33	43	25.7	312	4	US-09-176-666-4	Sequence 4, Appl1
34	43	25.7	314	4	US-09-176-666-4	Sequence 4, Appl1
35	43	25.7	316	4	US-09-176-666-4	Sequence 4, Appl1
36	43	25.7	318	4	US-09-176-666-4	Sequence 4, Appl1
37	43	25.7	320	4	US-09-176-666-4	Sequence 4, Appl1
38	43	25.7	322	4	US-09-176-666-4	Sequence 4, Appl1
39	43	25.7	324	4	US-09-176-666-4	Sequence 4, Appl1
40	43	25.7	326	4	US-09-176-666-4	Sequence 4, Appl1
41	43	25.7	328	4	US-09-176-666-4	Sequence 4, Appl1
42	43	25.7	330	4	US-09-176-666-4	Sequence 4, Appl1
43	43	25.7	332	4	US-09-176-666-4	Sequence 4, Appl1
44	43	25.7	334	4	US-09-176-666-4	Sequence 4, Appl1
45	43	25.7	336	4	US-09-176-666-4	Sequence 4, Appl1

RESULT 1
US-09-081-345-16
Sequence 16, Application US-09-081-345
GENERAL INFORMATION:
APPLICANT: Bahija Jallal
APPLICANT: Gregory D. Plouman
TITLE OF INVENTION: DIAGNOSTIC AND TREATMENT OF
NUMBER OF SEQUENCES: 18
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Lyon & Lyon
STREET: 333 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FASTSEQ for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US-09-081-345
FILING DATE: Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/047,222
FILING DATE: May 20, 1997
ATTORNEY/AGENT INFORMATION:
NAME: Walburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/EXCISE NUMBER: 3,347,253
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 30 amino acids
TYPE: amino acid
STRANDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-09-081-345-16
Query Match 100.0% Score 161.0 FR 4: Length 30:
Best Local Similarity 100.0% Pred. No. 4, 5, 16:

1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525

```

1 NUMBER OF ENTRIES: 45
2
3 CORRESPONDENT ADDRESS:
4 ADDRESS: 750 & Richardson Pkwy
5 STREET: 225 Franklin Street
6 CITY: Boston
7 STATE: MA
8 COUNTRY: US
9 ZIP: 02110-2804
10
11 COMPUTER READABLE FORM:
12 RECTOR TYPE: Diskette
13 COMPUTER: IBM Compat ible
14 OPERATING SYSTEM: Windows95
15 SOFTWARE: FASTSEQ for Windows Version 2.3
16 CURRENT APPLICATION DATA:
17 APPLICATION NUMBER: 05/06/870.518
18 FILING DATE: 06-JUN-1997
19
20 PRIOR APPLICATION DATA:
21 APPLICATION NUMBER: 60/019,219
22 FILING DATE: 06-JUN-1996
23 ATTORNEY/AGENT INFORMATION:
24 NAME: FASSO, Peter J.
25 REGISTRATION NUMBER: 42,983
26 TELEPHONE/TELEFAX NUMBER: 617/542-102001
27 TELEPHONE: 617/542-5070
28 TELEFAX: 617/542-8906
29
30 TELE: 200154
31
32 INFORMATION FOR SEQ ID NO: 4:
33 SEQUENCE CHARACTERISTICS:
34 LENGTH: 459 amino acids
35 TYPE: amino acid
36
37 TOPOLOGY: linear
38
39 MOLECULE TYPE: protein
40
41 DS-08-870-518-4
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974

```


[illegible]

90 DSKV+VNI NNI NN

Q7	6	DSKHQ1IRACGVKHHQ	21
	111	: : : : :	11
D3	90	DSKVEVNNLNNLNNHH	105


```

GENERAL INFORMATION INFORMATION:
  LENGTH: 415-815-9555
  FAX: 415-845-4156
  NAME: UNKNOWN
  SEQUENCE CHARACTERISTICS:
  LENGTH: 120 amino acids
  TYPE: amino acid
  STRANDEDNESS: single
  TOPOLOGY: linear
  IMMEDIATE SOURCE:
  LIBRARY: GenBank
  ACC: 156816
  SOURCE: Described in: SEQ ID NO: 4

Query Match: 28.0% Score 45; DB 4; Length 120;
Host Local Similarity 48.8%; Pred. No. 12;
Matches 5; Conservative 5; Mismatches 4; Indels 0; Gaps 0;

14. 156816:US:09-822-295-16
15. 156816:US:09-822-295-16
16. 156816:US:09-822-295-16
17. 156816:US:09-822-295-16
18. 156816:US:09-822-295-16
19. 156816:US:09-822-295-16
20. 156816:US:09-822-295-16
21. 156816:US:09-822-295-16
22. 156816:US:09-822-295-16
23. 156816:US:09-822-295-16
24. 156816:US:09-822-295-16
25. 156816:US:09-822-295-16
26. 156816:US:09-822-295-16
27. 156816:US:09-822-295-16
28. 156816:US:09-822-295-16
29. 156816:US:09-822-295-16
30. 156816:US:09-822-295-16
31. 156816:US:09-822-295-16
32. 156816:US:09-822-295-16
33. 156816:US:09-822-295-16
34. 156816:US:09-822-295-16
35. 156816:US:09-822-295-16
36. 156816:US:09-822-295-16
37. 156816:US:09-822-295-16
38. 156816:US:09-822-295-16
39. 156816:US:09-822-295-16
40. 156816:US:09-822-295-16
41. 156816:US:09-822-295-16
42. 156816:US:09-822-295-16
43. 156816:US:09-822-295-16
44. 156816:US:09-822-295-16
45. 156816:US:09-822-295-16
46. 156816:US:09-822-295-16
47. 156816:US:09-822-295-16
48. 156816:US:09-822-295-16
49. 156816:US:09-822-295-16
50. 156816:US:09-822-295-16
51. 156816:US:09-822-295-16
52. 156816:US:09-822-295-16
53. 156816:US:09-822-295-16
54. 156816:US:09-822-295-16
55. 156816:US:09-822-295-16
56. 156816:US:09-822-295-16
57. 156816:US:09-822-295-16
58. 156816:US:09-822-295-16
59. 156816:US:09-822-295-16
60. 156816:US:09-822-295-16
61. 156816:US:09-822-295-16
62. 156816:US:09-822-295-16
63. 156816:US:09-822-295-16
64. 156816:US:09-822-295-16
65. 156816:US:09-822-295-16
66. 156816:US:09-822-295-16
67. 156816:US:09-822-295-16
68. 156816:US:09-822-295-16
69. 156816:US:09-822-295-16
70. 156816:US:09-822-295-16
71. 156816:US:09-822-295-16
72. 156816:US:09-822-295-16
73. 156816:US:09-822-295-16
74. 156816:US:09-822-295-16
75. 156816:US:09-822-295-16
76. 156816:US:09-822-295-16
77. 156816:US:09-822-295-16
78. 156816:US:09-822-295-16
79. 156816:US:09-822-295-16
80. 156816:US:09-822-295-16
81. 156816:US:09-822-295-16
82. 156816:US:09-822-295-16
83. 156816:US:09-822-295-16
84. 156816:US:09-822-295-16
85. 156816:US:09-822-295-16
86. 156816:US:09-822-295-16
87. 156816:US:09-822-295-16
88. 156816:US:09-822-295-16
89. 156816:US:09-822-295-16
90. 156816:US:09-822-295-16
91. 156816:US:09-822-295-16
92. 156816:US:09-822-295-16
93. 156816:US:09-822-295-16
94. 156816:US:09-822-295-16
95. 156816:US:09-822-295-16
96. 156816:US:09-822-295-16
97. 156816:US:09-822-295-16
98. 156816:US:09-822-295-16
99. 156816:US:09-822-295-16
100. 156816:US:09-822-295-16

```

```

Query Match: 28.0% Score 45; DB 4; Length 1199;
Host Local Similarity 34.8%; Pred. No. 196-02;
Matches 8; Conservative 4; Mismatches 11; Indels 0; Gaps 0;

1. 156816:US:09-822-295-16
2. 156816:US:09-822-295-16
3. 156816:US:09-822-295-16
4. 156816:US:09-822-295-16
5. 156816:US:09-822-295-16
6. 156816:US:09-822-295-16
7. 156816:US:09-822-295-16
8. 156816:US:09-822-295-16
9. 156816:US:09-822-295-16
10. 156816:US:09-822-295-16
11. 156816:US:09-822-295-16
12. 156816:US:09-822-295-16
13. 156816:US:09-822-295-16
14. 156816:US:09-822-295-16
15. 156816:US:09-822-295-16
16. 156816:US:09-822-295-16
17. 156816:US:09-822-295-16
18. 156816:US:09-822-295-16
19. 156816:US:09-822-295-16
20. 156816:US:09-822-295-16
21. 156816:US:09-822-295-16
22. 156816:US:09-822-295-16
23. 156816:US:09-822-295-16
24. 156816:US:09-822-295-16
25. 156816:US:09-822-295-16
26. 156816:US:09-822-295-16
27. 156816:US:09-822-295-16
28. 156816:US:09-822-295-16
29. 156816:US:09-822-295-16
30. 156816:US:09-822-295-16
31. 156816:US:09-822-295-16
32. 156816:US:09-822-295-16
33. 156816:US:09-822-295-16
34. 156816:US:09-822-295-16
35. 156816:US:09-822-295-16
36. 156816:US:09-822-295-16
37. 156816:US:09-822-295-16
38. 156816:US:09-822-295-16
39. 156816:US:09-822-295-16
40. 156816:US:09-822-295-16
41. 156816:US:09-822-295-16
42. 156816:US:09-822-295-16
43. 156816:US:09-822-295-16
44. 156816:US:09-822-295-16
45. 156816:US:09-822-295-16
46. 156816:US:09-822-295-16
47. 156816:US:09-822-295-16
48. 156816:US:09-822-295-16
49. 156816:US:09-822-295-16
50. 156816:US:09-822-295-16
51. 156816:US:09-822-295-16
52. 156816:US:09-822-295-16
53. 156816:US:09-822-295-16
54. 156816:US:09-822-295-16
55. 156816:US:09-822-295-16
56. 156816:US:09-822-295-16
57. 156816:US:09-822-295-16
58. 156816:US:09-822-295-16
59. 156816:US:09-822-295-16
60. 156816:US:09-822-295-16
61. 156816:US:09-822-295-16
62. 156816:US:09-822-295-16
63. 156816:US:09-822-295-16
64. 156816:US:09-822-295-16
65. 156816:US:09-822-295-16
66. 156816:US:09-822-295-16
67. 156816:US:09-822-295-16
68. 156816:US:09-822-295-16
69. 156816:US:09-822-295-16
70. 156816:US:09-822-295-16
71. 156816:US:09-822-295-16
72. 156816:US:09-822-295-16
73. 156816:US:09-822-295-16
74. 156816:US:09-822-295-16
75. 156816:US:09-822-295-16
76. 156816:US:09-822-295-16
77. 156816:US:09-822-295-16
78. 156816:US:09-822-295-16
79. 156816:US:09-822-295-16
80. 156816:US:09-822-295-16
81. 156816:US:09-822-295-16
82. 156816:US:09-822-295-16
83. 156816:US:09-822-295-16
84. 156816:US:09-822-295-16
85. 156816:US:09-822-295-16
86. 156816:US:09-822-295-16
87. 156816:US:09-822-295-16
88. 156816:US:09-822-295-16
89. 156816:US:09-822-295-16
90. 156816:US:09-822-295-16
91. 156816:US:09-822-295-16
92. 156816:US:09-822-295-16
93. 156816:US:09-822-295-16
94. 156816:US:09-822-295-16
95. 156816:US:09-822-295-16
96. 156816:US:09-822-295-16
97. 156816:US:09-822-295-16
98. 156816:US:09-822-295-16
99. 156816:US:09-822-295-16
100. 156816:US:09-822-295-16

```


Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains. The *Agrobacterium* strains were grown in YEA medium for 24 h at 28 °C. The cell concentration of the strains was adjusted to 10⁸ cells/ml. The cell suspension was then diluted with distilled water to the concentration of 10⁶ cells/ml. The cell suspension was then mixed with the plant tissue and the transformation efficiency was determined. The results are shown in Table 1.

[illegible]

1. *Phragmites australis* (Cav.) Trin. ex Steud.

[illegible]

1 APPLICANT: WATKINS, COLIN K.
 2 APPLICANT: WOOD, WILLIAM L.
 3 APPLICANT: ZHANG, ZHENGLI
 4 TITLE OF INVENTION: SEQUENCING AND TRANSMEMBRANE POLYPEPTIDES AND NOVEL
 5 FILE REFERENCE: P44-081145
 6 CURRENT FILING DATE: 2002-06-19
 7 PRIORITY APPLICATION REMOVED: See File Wrapper of P44-
 8 NUMBER OF SEQ ID NOS: 912
 9 SEQ ID NO: 440
 10 LENGTH: 1115
 11 TYPE: PRT
 12 ORGANISM: Homo Sapien
 13 US-10-175-752-440
 14 Query Match: 29.2% Score 47; DB 9; Length 1115;
 15 Best Local Similarity: 47.6% Prod. No. 2,20-022;
 16 Matches: 10; Conservative: 2; Mismatches: 5; Gaps: 1;

17 1 YSLPYEKQIIRNSVKKHH 21
 18 111
 19 1002 YLPPDSIHQDQ--- PHHD 1018

20 RESULT 11
 21 US-10-175-752-440
 22 Sequence 440, Application US/1176482
 23 Publication No. US20040022296A1
 24 ORIGIN: INVENTOR:
 25 APPLICANT: Baker, Kevin L.
 26 APPLICANT: Chen, Jiah
 27 APPLICANT: Casanoves, Eric
 28 APPLICANT: Gaddard, Audrey
 29 APPLICANT: Gadowski, Paul J.
 30 APPLICANT: Gurev, Asaf D.
 31 APPLICANT: Han, James
 32 APPLICANT: Smith, Victoria
 33 APPLICANT: Waladad, Yvelin K.
 34 APPLICANT: Wood, William L.
 35 APPLICANT: Zhang, Zhengli
 36 TITLE OF INVENTION: SEQUENCING AND TRANSMEMBRANE POLYPEPTIDES AND NOVEL
 37 FILE REFERENCE: P44-081145
 38 CURRENT FILING DATE: 2002-06-19
 39 PRIORITY APPLICATION REMOVED: See File Wrapper of P44-
 40 NUMBER OF SEQ ID NOS: 912
 41 SEQ ID NO: 440
 42 LENGTH: 1115
 43 TYPE: PRT
 44 ORGANISM: Homo Sapien
 45 US-10-175-752-440
 46 Query Match: 29.2% Score 47; DB 9; Length 1115;
 47 Best Local Similarity: 47.6% Prod. No. 2,20-022;
 48 Matches: 10; Conservative: 2; Mismatches: 5; Gaps: 1;

49 1 YSLPYEKQIIRNSVKKHH 21
 50 111
 51 1002 YLPPDSIHQDQ--- PHHD 1018

52 RESULT 12
 53 US-10-176-482-440
 54 Sequence 440, Application US/1176482
 55 Publication No. US20040022296A1
 56 ORIGIN: INVENTOR:
 57 APPLICANT: Baker, Kevin L.
 58 APPLICANT: Chen, Jiah
 59 APPLICANT: Casanoves, Eric
 60 APPLICANT: Gaddard, Audrey
 61 APPLICANT: Gadowski, Paul J.
 62 APPLICANT: Han, James
 63 APPLICANT: Smith, Victoria
 64 APPLICANT: Waladad, Yvelin K.
 65 APPLICANT: Wood, William L.
 66 APPLICANT: Zhang, Zhengli
 67 TITLE OF INVENTION: SEQUENCING AND TRANSMEMBRANE POLYPEPTIDES AND NOVEL
 68 FILE REFERENCE: P44-081145
 69 CURRENT FILING DATE: 2002-06-19
 70 PRIORITY APPLICATION REMOVED: See File Wrapper of P44-
 71 NUMBER OF SEQ ID NOS: 912
 72 SEQ ID NO: 440
 73 LENGTH: 1115
 74 TYPE: PRT
 75 ORGANISM: Homo Sapien
 76 US-10-176-482-440
 77 Query Match: 29.2% Score 47; DB 9; Length 1115;
 78 Best Local Similarity: 47.6% Prod. No. 2,20-022;
 79 Matches: 10; Conservative: 2; Mismatches: 5; Gaps: 1;

80 1 YSLPYEKQIIRNSVKKHH 21
 81 111
 82 1002 YLPPDSIHQDQ--- PHHD 1018

i
u

software version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

MM Protein - Protein search, using SW model

Run date: July 8, 2003, 12:07:22 : Search time 11.8641 seconds
(without alignments)
243,006 Million cell updates/sec

Database: NCBI-822-295-16

Protein source: 1 YK1YD5KHQ1ENASVKNHESALGVTSY 30

Sequence label: P000992

Query: 10.0 : Expect 0.5

Score: 28.24 seqs: 9614422 residues

Hit 1: 28.24 seqs: 9614422 residues

Maximum hit seq length: 20000000

Maximum hit seq length: 20000000

Fast processing: Minimum Match: 0.6

Maximum Match: 1.00

Database: 11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

11.741*

Prod. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DP	ID	Description
1	59	4.8	459	2	137704	zinc finger protein
2	56	4.8	459	2	143538	zinc finger protein
3	52	5.3	469	2	149105	putative RNA-depen
4	52	5.3	469	2	149105	putative RNA-depen
5	52	5.3	469	2	149105	putative RNA-depen
6	52	5.3	469	2	149105	putative RNA-depen
7	52	5.3	469	2	149105	putative RNA-depen
8	52	5.3	469	2	149105	putative RNA-depen
9	52	5.3	469	2	149105	putative RNA-depen
10	52	5.3	469	2	149105	putative RNA-depen
11	52	5.3	469	2	149105	putative RNA-depen
12	52	5.3	469	2	149105	putative RNA-depen
13	52	5.3	469	2	149105	putative RNA-depen
14	52	5.3	469	2	149105	putative RNA-depen
15	52	5.3	469	2	149105	putative RNA-depen
16	52	5.3	469	2	149105	putative RNA-depen
17	52	5.3	469	2	149105	putative RNA-depen
18	52	5.3	469	2	149105	putative RNA-depen
19	52	5.3	469	2	149105	putative RNA-depen
20	52	5.3	469	2	149105	putative RNA-depen
21	52	5.3	469	2	149105	putative RNA-depen
22	52	5.3	469	2	149105	putative RNA-depen
23	52	5.3	469	2	149105	putative RNA-depen
24	52	5.3	469	2	149105	putative RNA-depen
25	52	5.3	469	2	149105	putative RNA-depen
26	52	5.3	469	2	149105	putative RNA-depen
27	52	5.3	469	2	149105	putative RNA-depen
28	52	5.3	469	2	149105	putative RNA-depen
29	52	5.3	469	2	149105	putative RNA-depen
30	52	5.3	469	2	149105	putative RNA-depen

ALIGNMENTS

30	46	28.6	28.2	2	137704	zinc finger protein
31	46	28.6	28.2	2	137704	zinc finger protein
32	46	28.6	28.2	2	137704	zinc finger protein
33	46	28.6	28.2	2	137704	zinc finger protein
34	46	28.6	28.2	2	137704	zinc finger protein
35	46	28.6	28.2	2	137704	zinc finger protein
36	46	28.6	28.2	2	137704	zinc finger protein
37	46	28.6	28.2	2	137704	zinc finger protein
38	46	28.6	28.2	2	137704	zinc finger protein
39	46	28.6	28.2	2	137704	zinc finger protein
40	46	28.6	28.2	2	137704	zinc finger protein
41	46	28.6	28.2	2	137704	zinc finger protein
42	46	28.6	28.2	2	137704	zinc finger protein
43	46	28.6	28.2	2	137704	zinc finger protein
44	46	28.6	28.2	2	137704	zinc finger protein
45	46	28.6	28.2	2	137704	zinc finger protein

RESULT 1
137704
zinc finger protein zpr1 - fission yeast (schizosaccharomyces pombe)
C:Species: Schizosaccharomyces pombe
C:Date: 03-Nov-1999 #Sequence revision 34-Nov-1999 #Entry update 21-Jun-2000
C:Accession: T37704
R:Murphy, L.; Harris, D.; Wood, V.; Petrij, B.; de Jong, M.A.
submitted to the EMBL Data Library, June 1997
A:Reference number: 221738
A:Accession: T37704
A:Status: Preliminary; translated; 35, 286, 1000
A:Molecule type: DNA
A:Residues: 1-459 (508)
A:Cross-references: EMBL:29709; PDB:2B1011; NCB:2B1011; NCB:2B1011; NCB:2B1011
A:Experimental source: strain 972h; cosmid c15A10
C:Genetics:
A:Gene: zpr1; SPDB:SPDB15A10.04c
A:Map position: 1
C:Superfamily: hypothetical protein YGR211w

Query Match 34.8% Score 59 DB 2 Length 459
Best Local Similarity 50.0% Prod. No. 2.47
Matches 12: Conservative 3, Miscellaneous 9, Indels 0, Gaps 0
ID 224 P000992ENASVKNHESALGVTSY 247

RESULT 2
143538
zinc finger protein zpr1 - fission yeast (schizosaccharomyces pombe)
C:Species: Schizosaccharomyces pombe
C:Date: 21-Jun-2000 #Sequence revision 21-Jun-2000 #Entry update 21-Jun-2000
C:Accession: T43538
R:Gatcheva, V.; Harris, D.; Wood, V.; Petrij, B.; de Jong, M.A.
submitted to the EMBL Data Library, August 1997
A:Description: translational regulation by the ERF1 signal transduction pathway.
A:Reference number: 222557
A:Accession: T43538
A:Status: Preliminary; translated from cDNA; 286, 1000
A:Molecule type: DNA
A:Residues: 1-459 (508)
A:Cross-references: EMBL:AF019768; PDB:2B1011; NCB:2B1011; NCB:2B1011
C:Genetics:
A:Gene: zpr1
C:Superfamily: hypothetical protein YGR211w
Query Match 34.8% Score 59 DB 2 Length 459
Best Local Similarity 50.0% Prod. No. 2.47
Matches 12: Conservative 3, Miscellaneous 9, Indels 0, Gaps 0

This document is copyright © 2006 by Swissmed AG. The Swiss Institute of Biomedicine and the EMU contribution to the European Biomedicine Institute. There are no restrictions on its distribution or use by non profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license from Swissmed AG. www.swissmed.ch and phone +41 78 829 1000 or email to liverpool@swissmed.ch

RESULT 5	ACN3_PIG	STANDARD	ERT	116 AA
ID	ACN3_PIG			
AC	P24020:			
DT	01-MAR-1992	(POL_21, created)		
DT	01-MAR-1992	(REL_21, last sequence update)		
DI	01-FEB-1996	(REL_33, last annotation update)		
DE	Carboxylate-binding protein ACN3 (Zona pellucida-binding protein ACN3)			
DT	ACN3_3	(Spermidinase ACN3)		
OS	Sus scrofa (pig)			
OC	Eukaryota; Metazoa; Chordata; Cladete; Vertebrata; Euteleostomi;			
OC	Mammalia; Eutheria; Cetartiodactyla; Suidae; Suidae; Sus.			
OX	NCBI_TaxID:9823;			
IN	[1]			
RP	SEQUENCE AND DISULFIDE BONDS.			
RC	FLISUSE:SPERM;			

[illegible]

(protein A)
at leaste halibut neovirus necrosis virus (AANV).
virus; ssRNA positive strand viruses) no RNA stage. Nucleotide
nucleotide us.
NCBI TaxID : 9486;
[1]
SEQUENCE FROM N.A.
STRAIN AB0061AC:
neovirus 1.; Neofund A.H.:
"the sequence of RNA from Atlantic halibut neovirus necrosis virus
(AANV)".
KJ676003 (JUN 2009) To the EMBL/GenBank/DDBJ databases,
I FUNCTION: Replicates the viral genome which is composed of two RNA
segments, RNA1 and RNA2.
CATALYTIC ACTIVITY: N nucleoside triphosphate + N diphosphate ->
dNMP + H₂O
SIMILARITY: BELONGS TO THE NEOVIRUSES RNA POLYMERASE FAMILY.

This SWISS-PROT entry is copyright . It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outbreak center at European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is preserved. Usage by and for commercial purposes without prior written permission is prohibited.

EMBL: AJ001165; NC_017792.1;
NEOVIRUS RNA DIRECTED RNA POLYMERASE,
GENEPOOL 981 AA. 110728 BP. GCGTCGCTGGTGATCAAGCAGCGA;
Query Match 28.6%; Score 46; DR 1; Length 981;
Base Count: A:107 C:177 G:146 T:661 Total: 1191
Matches 92 Conserved Ivs 62 Mismatches 112 Indels 0 Pairs 0;

5. VIRSHUSTRANSKRIBESACTIVITY 66
[1] [1] [1] [1] [1] [1] [1] [1] [1] [1]
520 YRAAYPRRHSIVTRHNOVKLSITY 645

RESULT 12
WHIS YEAST
10 WHIS YEAST STANDARD, ENZ, 661 AA,
P34761;
01 FEB-1994 (Ref., 28, Updated)
01 FEB-1994 (Ref., 28, Last sequence update)
16 OCT-2001 (Ref., 40, Last annotation update)
DE WHIS Protein;
EN WHIS OR NM_11776 OR N1382.
OS Saccharomyces cerevisiae (Baker's yeast);
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OX NCBI_TaxID 4932;
RN
PN
SEQUENCE FROM N.A.
Strain R.S.; Putcher A.B.:
Submitted (AUG 1993) to the EMBL/GenBank/DDBJ databases
[1]
[1]
SEQUENCE FROM N.A.
Strain J2506 / F11679;
BA MEDLINE 9524289; PubMed 7725709;
Journal J. L.; Foster F.; Purfield B.; Robinson A.;
JA 217 Kt DNA segment on left arm of yeast chromosome XIV
RT carries WHIS, ORF2, SPYII, SPXV, an homologous to the host Shoox gene
KT SSI1 and R now open reading frames of unknown function."
EL Yeast 10:1163-1165(1994).
CC 1. FUNCTION: INVENTED IN STEVE SHOOX POSSIBLE RNA BINDING PROTEIN.
CC 1. SIMILARITY: CONTAINS 1 RNA RECOGNITION MOTIF (RRM).

This SWISS-PROT entry is copyright . It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outbreak center at European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is preserved. Usage by and for commercial purposes without prior written permission is prohibited.

[illegible]

01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
00

EMBL: X55942; CAA3347.1;
EMBL: AL079356; CAA55605.1;
PIR: S11973; S11973.
Complete Proteome
SEQUENCE 157 AA; 16669 MW; 216306 Da (PIR) 36542;
Ducty Match 28.0%; Score: 45; 15; 1; month 157;
Post Local Similarity 43.0%; Prol. No. 13
Matches 7; Conserved 6; Missed 6; 4; 100.0; 1; 100.0;
3 LPYSDKIDKASNNK 18
1 1 1 1 1 1 1
89 LPYIMRIRFENAGIVE 104
RESID 14
APPA MAIZE
10 APPA MAIZE STANDARD P01 204 AA
11 P33489;
12 01-FEB-1994 (001 28, Created)
13 01-FEB-1994 (001 28, Last sequence update)
14 01 NOV 1995 (001 32, Last annotation update)
15 Author: Elnikova I (001 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 7

Search time 5.146
 (without alignment)
 60.892 Million cell updates/sec

Search time 14.5075 seconds

Search time 14.5075 seconds
 (with alignment)

60.892 Million cell updates/sec

Search time 14.5075 seconds
 (with alignment)

Search time 14.5075 seconds
 (with alignment)

Search time 14.5075 seconds
 (with alignment)

Search time 14.5075 seconds
 (with alignment)

Search time 14.5075 seconds
 (with alignment)

Search time 14.5075 seconds
 (with alignment)

Search time 14.5075 seconds
 (with alignment)

Print Results: The number of results predicted by chance to have a
 significance level of 0.01 is equal to the score of the result being printed.
 Results derived by analysis of the total score distribution.

SUMMARY

Score	Match	Description
154	US 09-081-445-17	Sequence 17, Appl
144	US 09-081-445-2	Sequence 2, Appl
134	US 09-081-445-2	Sequence 2, Appl
124	US 09-081-445-2	Sequence 2, Appl
114	US 09-081-445-2	Sequence 2, Appl
104	US 09-081-445-2	Sequence 2, Appl
94	US 09-081-445-2	Sequence 2, Appl
84	US 09-081-445-2	Sequence 2, Appl
74	US 09-081-445-2	Sequence 2, Appl
64	US 09-081-445-2	Sequence 2, Appl
54	US 09-081-445-2	Sequence 2, Appl
44	US 09-081-445-2	Sequence 2, Appl
34	US 09-081-445-2	Sequence 2, Appl
24	US 09-081-445-2	Sequence 2, Appl
14	US 09-081-445-2	Sequence 2, Appl
4	US 09-081-445-2	Sequence 2, Appl

28	43	27.2	1561	4	US 09-081-445-17	Sequence 17, Appl
29	42	26.6	1561	1	US 09-081-445-2	Sequence 2, Appl
30	42	26.6	1561	2	US 09-081-445-2	Sequence 2, Appl
31	42	26.6	1561	3	US 09-081-445-2	Sequence 2, Appl
32	42	26.6	1561	4	US 09-081-445-2	Sequence 2, Appl
33	42	26.6	1561	5	US 09-081-445-2	Sequence 2, Appl
34	42	26.6	1561	6	US 09-081-445-2	Sequence 2, Appl
35	42	26.6	1561	7	US 09-081-445-2	Sequence 2, Appl
36	42	26.6	1561	8	US 09-081-445-2	Sequence 2, Appl
37	42	26.6	1561	9	US 09-081-445-2	Sequence 2, Appl
38	42	26.6	1561	10	US 09-081-445-2	Sequence 2, Appl
39	42	26.6	1561	11	US 09-081-445-2	Sequence 2, Appl
40	42	26.6	1561	12	US 09-081-445-2	Sequence 2, Appl
41	42	26.6	1561	13	US 09-081-445-2	Sequence 2, Appl
42	42	26.6	1561	14	US 09-081-445-2	Sequence 2, Appl
43	42	26.6	1561	15	US 09-081-445-2	Sequence 2, Appl
44	42	26.6	1561	16	US 09-081-445-2	Sequence 2, Appl
45	42	26.6	1561	17	US 09-081-445-2	Sequence 2, Appl

1 Received by Application US70681445
 2 Form No. 2004
 3 GENERAL INFORMATION
 4 APPLICANT: Bahadur Lalal
 5 TITLE OF INVENTION: PROCEEDING D. Flewman
 6 TITLE OF INVENTION: PROCEEDING D. Flewman
 7 NUMBER OF SEQUENCES: 18
 8 ADDRESS: 1000
 9 STREET: 64 West Fifth Street
 10 CITY: Los Angeles
 11 STATE: California
 12 COUNTRY: USA
 13 TELEPHONE: 407-1-200
 14 TELETYPE: 407-1-200
 15 ADDRESS: 1000
 16 STREET: 64 West Fifth Street
 17 CITY: Los Angeles
 18 STATE: California
 19 COUNTRY: USA
 20 TELEPHONE: 407-1-200
 21 TELETYPE: 407-1-200
 22 ADDRESS: 1000
 23 STREET: 64 West Fifth Street
 24 CITY: Los Angeles
 25 STATE: California
 26 COUNTRY: USA
 27 TELEPHONE: 407-1-200
 28 TELETYPE: 407-1-200
 29 ADDRESS: 1000
 30 STREET: 64 West Fifth Street
 31 CITY: Los Angeles
 32 STATE: California
 33 COUNTRY: USA
 34 TELEPHONE: 407-1-200
 35 TELETYPE: 407-1-200
 36 ADDRESS: 1000
 37 STREET: 64 West Fifth Street
 38 CITY: Los Angeles
 39 STATE: California
 40 COUNTRY: USA
 41 TELEPHONE: 407-1-200
 42 TELETYPE: 407-1-200
 43 ADDRESS: 1000
 44 STREET: 64 West Fifth Street
 45 CITY: Los Angeles
 46 STATE: California
 47 COUNTRY: USA
 48 TELEPHONE: 407-1-200
 49 TELETYPE: 407-1-200
 50 ADDRESS: 1000
 51 STREET: 64 West Fifth Street
 52 CITY: Los Angeles
 53 STATE: California
 54 COUNTRY: USA
 55 TELEPHONE: 407-1-200
 56 TELETYPE: 407-1-200
 57 ADDRESS: 1000
 58 STREET: 64 West Fifth Street
 59 CITY: Los Angeles
 60 STATE: California
 61 COUNTRY: USA
 62 TELEPHONE: 407-1-200
 63 TELETYPE: 407-1-200
 64 ADDRESS: 1000
 65 STREET: 64 West Fifth Street
 66 CITY: Los Angeles
 67 STATE: California
 68 COUNTRY: USA
 69 TELEPHONE: 407-1-200
 70 TELETYPE: 407-1-200
 71 ADDRESS: 1000
 72 STREET: 64 West Fifth Street
 73 CITY: Los Angeles
 74 STATE: California
 75 COUNTRY: USA
 76 TELEPHONE: 407-1-200
 77 TELETYPE: 407-1-200
 78 ADDRESS: 1000
 79 STREET: 64 West Fifth Street
 80 CITY: Los Angeles
 81 STATE: California
 82 COUNTRY: USA
 83 TELEPHONE: 407-1-200
 84 TELETYPE: 407-1-200
 85 ADDRESS: 1000
 86 STREET: 64 West Fifth Street
 87 CITY: Los Angeles
 88 STATE: California
 89 COUNTRY: USA
 90 TELEPHONE: 407-1-200
 91 TELETYPE: 407-1-200
 92 ADDRESS: 1000
 93 STREET: 64 West Fifth Street
 94 CITY: Los Angeles
 95 STATE: California
 96 COUNTRY: USA
 97 TELEPHONE: 407-1-200
 98 TELETYPE: 407-1-200
 99 ADDRESS: 1000
 100 STREET: 64 West Fifth Street
 101 CITY: Los Angeles
 102 STATE: California
 103 COUNTRY: USA
 104 TELEPHONE: 407-1-200
 105 TELETYPE: 407-1-200
 106 ADDRESS: 1000
 107 STREET: 64 West Fifth Street
 108 CITY: Los Angeles
 109 STATE: California
 110 COUNTRY: USA
 111 TELEPHONE: 407-1-200
 112 TELETYPE: 407-1-200
 113 ADDRESS: 1000
 114 STREET: 64 West Fifth Street
 115 CITY: Los Angeles
 116 STATE: California
 117 COUNTRY: USA
 118 TELEPHONE: 407-1-200
 119 TELETYPE: 407-1-200
 120 ADDRESS: 1000
 121 STREET: 64 West Fifth Street
 122 CITY: Los Angeles
 123 STATE: California
 124 COUNTRY: USA
 125 TELEPHONE: 407-1-200
 126 TELETYPE: 407-1-200
 127 ADDRESS: 1000
 128 STREET: 64 West Fifth Street
 129 CITY: Los Angeles
 130 STATE: California
 131 COUNTRY: USA
 132 TELEPHONE: 407-1-200
 133 TELETYPE: 407-1-200
 134 ADDRESS: 1000
 135 STREET: 64 West Fifth Street
 136 CITY: Los Angeles
 137 STATE: California
 138 COUNTRY: USA
 139 TELEPHONE: 407-1-200
 140 TELETYPE: 407-1-200
 141 ADDRESS: 1000
 142 STREET: 64 West Fifth Street
 143 CITY: Los Angeles
 144 STATE: California
 145 COUNTRY: USA
 146 TELEPHONE: 407-1-200
 147 TELETYPE: 407-1-200
 148 ADDRESS: 1000
 149 STREET: 64 West Fifth Street
 150 CITY: Los Angeles
 151 STATE: California
 152 COUNTRY: USA
 153 TELEPHONE: 407-1-200
 154 TELETYPE: 407-1-200
 155 ADDRESS: 1000
 156 STREET: 64 West Fifth Street
 157 CITY: Los Angeles
 158 STATE: California
 159 COUNTRY: USA
 160 TELEPHONE: 407-1-200
 161 TELETYPE: 407-1-200
 162 ADDRESS: 1000
 163 STREET: 64 West Fifth Street
 164 CITY: Los Angeles
 165 STATE: California
 166 COUNTRY: USA
 167 TELEPHONE: 407-1-200
 168 TELETYPE: 407-1-200
 169 ADDRESS: 1000
 170 STREET: 64 West Fifth Street
 171 CITY: Los Angeles
 172 STATE: California
 173 COUNTRY: USA
 174 TELEPHONE: 407-1-200
 175 TELETYPE: 407-1-200
 176 ADDRESS: 1000
 177 STREET: 64 West Fifth Street
 178 CITY: Los Angeles
 179 STATE: California
 180 COUNTRY: USA
 181 TELEPHONE: 407-1-200
 182 TELETYPE: 407-1-200
 183 ADDRESS: 1000
 184 STREET: 64 West Fifth Street
 185 CITY: Los Angeles
 186 STATE: California
 187 COUNTRY: USA
 188 TELEPHONE: 407-1-200
 189 TELETYPE: 407-1-200
 190 ADDRESS: 1000
 191 STREET: 64 West Fifth Street
 192 CITY: Los Angeles
 193 STATE: California
 194 COUNTRY: USA
 195 TELEPHONE: 407-1-200
 196 TELETYPE: 407-1-200
 197 ADDRESS: 1000
 198 STREET: 64 West Fifth Street
 199 CITY: Los Angeles
 200 STATE: California
 201 COUNTRY: USA
 202 TELEPHONE: 407-1-200
 203 TELETYPE: 407-1-200
 204 ADDRESS: 1000
 205 STREET: 64 West Fifth Street
 206 CITY: Los Angeles
 207 STATE: California
 208 COUNTRY: USA
 209 TELEPHONE: 407-1-200
 210 TELETYPE: 407-1-200
 211 ADDRESS: 1000
 212 STREET: 64 West Fifth Street
 213 CITY: Los Angeles
 214 STATE: California
 215 COUNTRY: USA
 216 TELEPHONE: 407-1-200
 217 TELETYPE: 407-1-200
 218 ADDRESS: 1000
 219 STREET: 64 West Fifth Street
 220 CITY: Los Angeles
 221 STATE: California
 222 COUNTRY: USA
 223 TELEPHONE: 407-1-200
 224 TELETYPE: 407-1-200
 225 ADDRESS: 1000
 226 STREET: 64 West Fifth Street
 227 CITY: Los Angeles
 228 STATE: California
 229 COUNTRY: USA
 230 TELEPHONE: 407-1-200
 231 TELETYPE: 407-1-200
 232 ADDRESS: 1000
 233 STREET: 64 West Fifth Street
 234 CITY: Los Angeles
 235 STATE: California
 236 COUNTRY: USA
 237 TELEPHONE: 407-1-200
 238 TELETYPE: 407-1-200
 239 ADDRESS: 1000
 240 STREET: 64 West Fifth Street
 241 CITY: Los Angeles
 242 STATE: California
 243 COUNTRY: USA
 244 TELEPHONE: 407-1-200
 245 TELETYPE: 407-1-200
 246 ADDRESS: 1000
 247 STREET: 64 West Fifth Street
 248 CITY: Los Angeles
 249 STATE: California
 250 COUNTRY: USA
 251 TELEPHONE: 407-1-200
 252 TELETYPE: 407-1-200
 253 ADDRESS: 1000
 254 STREET: 64 West Fifth Street
 255 CITY: Los Angeles
 256 STATE: California
 257 COUNTRY: USA
 258 TELEPHONE: 407-1-200
 259 TELETYPE: 407-1-200
 260 ADDRESS: 1000
 261 STREET: 64 West Fifth Street
 262 CITY: Los Angeles
 263 STATE: California
 264 COUNTRY: USA
 265 TELEPHONE: 407-1-200
 266 TELETYPE: 407-1-200
 267 ADDRESS: 1000
 268 STREET: 64 West Fifth Street
 269 CITY: Los Angeles
 270 STATE: California
 271 COUNTRY: USA
 272 TELEPHONE: 407-1-

Q#	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
Q#	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
Q#	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
Q#	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
Q#	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
Q#	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
Q#	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	4																																																					

[illegible][illegible]

[illegible]

Variable	Mean	SD	Median	Mode	Range	Skewness	Kurtosis
Age	35.5	10.5	33.0	30.0	20.0-55.0	0.5	2.5
Gender	1.5	0.5	1.0	1.0	1.0-2.0	0.0	0.0
Marital Status	1.5	0.5	1.0	1.0	1.0-2.0	0.0	0.0
Education	12.5	1.5	12.0	12.0	10.0-15.0	0.0	0.0
Income	15.5	5.5	14.0	14.0	10.0-25.0	0.5	2.5
Occupation	1.5	0.5	1.0	1.0	1.0-2.0	0.0	0.0
Religion	1.5	0.5	1.0	1.0	1.0-2.0	0.0	0.0
Health Status	1.5	0.5	1.0	1.0	1.0-2.0	0.0	0.0
Stress Level	3.5	1.5	3.0	3.0	2.0-5.0	0.5	2.5
Life Satisfaction	4.5	1.5	4.0	4.0	3.0-6.0	0.5	2.5
Work-Life Balance	3.5	1.5	3.0	3.0	2.0-5.0	0.5	2.5
Family Support	4.5	1.5	4.0	4.0	3.0-6.0	0.5	2.5
Community Involvement	3.5	1.5	3.0	3.0	2.0-5.0	0.5	2.5
Personal Growth	4.5	1.5	4.0	4.0	3.0-6.0	0.5	2.5
Overall Well-being	4.5	1.5	4.0	4.0	3.0-6.0	0.5	2.5

[illegible][illegible][illegible]

Assessment	category	category	category
1. <i>Self</i>	1. <i>Self</i>	1. <i>Self</i>	1. <i>Self</i>
2. <i>Other</i>	2. <i>Other</i>	2. <i>Other</i>	2. <i>Other</i>
3. <i>Group</i>	3. <i>Group</i>	3. <i>Group</i>	3. <i>Group</i>
4. <i>Community</i>	4. <i>Community</i>	4. <i>Community</i>	4. <i>Community</i>
5. <i>World</i>	5. <i>World</i>	5. <i>World</i>	5. <i>World</i>
6. <i>Universe</i>	6. <i>Universe</i>	6. <i>Universe</i>	6. <i>Universe</i>
7. <i>God</i>	7. <i>God</i>	7. <i>God</i>	7. <i>God</i>
8. <i>Religion</i>	8. <i>Religion</i>	8. <i>Religion</i>	8. <i>Religion</i>
9. <i>Philosophy</i>	9. <i>Philosophy</i>	9. <i>Philosophy</i>	9. <i>Philosophy</i>
10. <i>Science</i>	10. <i>Science</i>	10. <i>Science</i>	10. <i>Science</i>
11. <i>Art</i>	11. <i>Art</i>	11. <i>Art</i>	11. <i>Art</i>
12. <i>Music</i>	12. <i>Music</i>	12. <i>Music</i>	12. <i>Music</i>
13. <i>Dance</i>	13. <i>Dance</i>	13. <i>Dance</i>	13. <i>Dance</i>
14. <i>Theater</i>	14. <i>Theater</i>	14. <i>Theater</i>	14. <i>Theater</i>
15. <i>History</i>	15. <i>History</i>	15. <i>History</i>	15. <i>History</i>
16. <i>Geography</i>	16. <i>Geography</i>	16. <i>Geography</i>	16. <i>Geography</i>
17. <i>Politics</i>	17. <i>Politics</i>	17. <i>Politics</i>	17. <i>Politics</i>
18. <i>Economics</i>	18. <i>Economics</i>	18. <i>Economics</i>	18. <i>Economics</i>
19. <i>Law</i>	19. <i>Law</i>	19. <i>Law</i>	19. <i>Law</i>
20. <i>Medicine</i>	20. <i>Medicine</i>	20. <i>Medicine</i>	20. <i>Medicine</i>
21. <i>Education</i>	21. <i>Education</i>	21. <i>Education</i>	21. <i>Education</i>
22. <i>Psychology</i>	22. <i>Psychology</i>	22. <i>Psychology</i>	22. <i>Psychology</i>
23. <i>Sociology</i>	23. <i>Sociology</i>	23. <i>Sociology</i>	23. <i>Sociology</i>
24. <i>Anthropology</i>	24. <i>Anthropology</i>	24. <i>Anthropology</i>	24. <i>Anthropology</i>
25. <i>Archaeology</i>	25. <i>Archaeology</i>	25. <i>Archaeology</i>	25. <i>Archaeology</i>
26. <i>Linguistics</i>	26. <i>Linguistics</i>	26. <i>Linguistics</i>	26. <i>Linguistics</i>
27. <i>Mathematics</i>	27. <i>Mathematics</i>	27. <i>Mathematics</i>	27. <i>Mathematics</i>
28. <i>Physics</i>	28. <i>Physics</i>	28. <i>Physics</i>	28. <i>Physics</i>
29. <i>Chemistry</i>	29. <i>Chemistry</i>	29. <i>Chemistry</i>	29. <i>Chemistry</i>
30. <i>Biology</i>	30. <i>Biology</i>	30. <i>Biology</i>	30. <i>Biology</i>
31. <i>Environmental Science</i>	31. <i>Environmental Science</i>	31. <i>Environmental Science</i>	31. <i>Environmental Science</i>
32. <i>Health Sciences</i>	32. <i>Health Sciences</i>	32. <i>Health Sciences</i>	32. <i>Health Sciences</i>
33. <i>Engineering</i>	33. <i>Engineering</i>	33. <i>Engineering</i>	33. <i>Engineering</i>
34. <i>Computer Science</i>	34. <i>Computer Science</i>	34. <i>Computer Science</i>	34. <i>Computer Science</i>
35. <i>Information Science</i>	35. <i>Information Science</i>	35. <i>Information Science</i>	35. <i>Information Science</i>
36. <i>Management Science</i>	36. <i>Management Science</i>	36. <i>Management Science</i>	36. <i>Management Science</i>
37. <i>Business Administration</i>	37. <i>Business Administration</i>	37. <i>Business Administration</i>	37. <i>Business Administration</i>
38. <i>Marketing</i>	38. <i>Marketing</i>	38. <i>Marketing</i>	38. <i>Marketing</i>
39. <i>Finance</i>	39. <i>Finance</i>	39. <i>Finance</i>	39. <i>Finance</i>
40. <i>Accounting</i>	40. <i>Accounting</i>	40. <i>Accounting</i>	40. <i>Accounting</i>
41. <i>Operations Management</i>	41. <i>Operations Management</i>	41. <i>Operations Management</i>	41. <i>Operations Management</i>
42. <i>Human Resources Management</i>	42. <i>Human Resources Management</i>	42. <i>Human Resources Management</i>	42. <i>Human Resources Management</i>
43. <i>Project Management</i>	43. <i>Project Management</i>	43. <i>Project Management</i>	43. <i>Project Management</i>
44. <i>Quality Management</i>	44. <i>Quality Management</i>	44. <i>Quality Management</i>	44. <i>Quality Management</i>
45. <i>Supply Chain Management</i>	45. <i>Supply Chain Management</i>	45. <i>Supply Chain Management</i>	45. <i>Supply Chain Management</i>
46. <i>Logistics Management</i>	46. <i>Logistics Management</i>	46. <i>Logistics Management</i>	46. <i>Logistics Management</i>
47. <i>Transportation Management</i>	47. <i>Transportation Management</i>	47. <i>Transportation Management</i>	47. <i>Transportation Management</i>
48. <i>International Management</i>	48. <i>International Management</i>	48. <i>International Management</i>	48. <i>International Management</i>
49. <i>Global Business</i>	49. <i>Global Business</i>	49. <i>Global Business</i>	49. <i>Global Business</i>
50. <i>Entrepreneurship</i>	50. <i>Entrepreneurship</i>	50. <i>Entrepreneurship</i>	50. <i>Entrepreneurship</i>
51. <i>Small Business Management</i>	51. <i>Small Business Management</i>	51. <i>Small Business Management</i>	51. <i>Small Business Management</i>
52. <i>Family Business</i>	52. <i>Family Business</i>	52. <i>Family Business</i>	52. <i>Family Business</i>
53. <i>Non-Profit Management</i>	53. <i>Non-Profit Management</i>	53. <i>Non-Profit Management</i>	53. <i>Non-Profit Management</i>
54. <i>Public Administration</i>	54. <i>Public Administration</i>	54. <i>Public Administration</i>	54. <i>Public Administration</i>
55. <i>Political Science</i>	55. <i>Political Science</i>	55. <i>Political Science</i>	55. <i>Political Science</i>
56. <i>International Relations</i>	56. <i>International Relations</i>	56. <i>International Relations</i>	56. <i>International Relations</i>
57. <i>Area Studies</i>	57. <i>Area Studies</i>	57. <i>Area Studies</i>	57. <i>Area Studies</i>
58. <i>Development Studies</i>	58. <i>Development Studies</i>	58. <i>Development Studies</i>	58. <i>Development Studies</i>
59. <i>Gender Studies</i>	59. <i>Gender Studies</i>	59. <i>Gender Studies</i>	59. <i>Gender Studies</i>
60. <i>Sexuality Studies</i>	60. <i>Sexuality Studies</i>	60. <i>Sexuality Studies</i>	60. <i>Sexuality Studies</i>
61. <i>Disability Studies</i>	61. <i>Disability Studies</i>	61. <i>Disability Studies</i>	61. <i>Disability Studies</i>
62. <i>Queer Studies</i>	62. <i>Queer Studies</i>	62. <i>Queer Studies</i>	62. <i>Queer Studies</i>
63. <i>Trans Studies</i>	6		

[illegible]

Fig. 1. A: A schematic diagram of the experimental setup. A subject is seated in a chair, viewing a video screen. A camera is positioned above the screen. A target is placed on the screen. A hand is positioned to move a lever. B: A schematic diagram of the experimental setup. A subject is seated in a chair, viewing a video screen. A camera is positioned above the screen. A target is placed on the screen. A hand is positioned to move a lever.

1. The first group of variables includes the demographic characteristics of the respondents, such as age, gender, and education level. These variables are used to control for potential confounding factors that may influence the relationship between the independent and dependent variables.

[illegible]

1. C_{10}H_8 (10.00 g, 0.077 mol) was dissolved in 100 mL of toluene.

[illegible]

The present report is devoted to the protein and coding sequences of human cytokeratin 10, which is the protein as expressed in human normal epidermal keratinocytes. The present report is the first of the two-volume report.

[illegible]

07-10-2015 10:05:00 AM

SEARCHED INDEXED SERIALIZED FILED
JUL 10 2003 FBI - NEW YORK

RE: [REDACTED] (NY 100-822-295)

TO: DIRECTOR, FBI (100-440000) FROM: SAC, NEW YORK (100-822-295)

SUBJECT: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

RE: [REDACTED] (NY 100-822-295)

20 45.5 28.8 1480 10 US-09-156-960-91 Sequence 91, Appl
21 45.5 28.8 2040 9 US-09-978-247A-27 Sequence 27, Appl
22 45.5 28.8 2107 9 US-09-815-179-8 Sequence 8, Appl
23 45 28.5 485 US-09-738-626-4559 Sequence 4559, Ap
24 45 28.5 560 10 US-09-810-244-10 Sequence 10, Appl
25 44.5 28.2 163 10 US-09-765-272-50 Sequence 50, Appl
26 44.5 28.2 223 9 US-10-125-540-436 Sequence 436, Ap
27 44.5 28.2 223 10 US-09-764-870-436 Sequence 436, Ap
28 44.5 28.2 1394 9 US-09-945-912-537 Sequence 57, Appl
29 44.5 28.2 1419 9 US-09-945-912-538 Sequence 58, Appl
30 44.5 28.2 1528 9 US-09-945-912-538 Sequence 58, Appl
31 44.5 28.2 1583 9 US-09-945-917-41 Sequence 4171, Ap
32 43 27.2 521 9 US-09-749-728B-19 Sequence 19, Appl
33 42.5 26.9 435 10 US-09-745-765-148 Sequence 148, Appl
34 42.5 26.9 523 10 US-09-815-242-5723 Sequence 5723, Ap
35 42.5 26.9 925 10 US-09-815-242-12651 Sequence 12651, A
36 42.5 26.9 83 9 US-09-924-879-606 Sequence 606, Appl
37 42 26.6 83 9 US-09-805-734-607 Sequence 607, Appl
38 42 26.6 206 10 US-09-815-242-13306 Sequence 13306, A
39 42 26.6 428 9 US-10-225-567A-136 Sequence 136, Appl
40 42 26.6 436 10 US-09-815-242-13042 Sequence 13042, A
41 42 26.6 820 10 US-09-846-582-35 Sequence 35, Appl
42 42 26.6 1161 8 US-08-910-380A-20 Sequence 20, Appl
43 42 26.6 1181 10 US-09-870-122-23 Sequence 23, Appl
44 42 26.6 5795 19 US-09-815-242-12610 Sequence 12610, A
45

ATTACHMENTS

RESULT 1
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17

US-09-822-295-17
US-09-822-295-17
US-09-822-295-17



[illegible]

[illegible]

1987 M. L. H. 1401 1511 1601 1701 1801 1901 2001 2101 2201 2301 2401 2501 2601 2701 2801 2901 3001 3101 3201 3301 3401 3501 3601 3701 3801 3901 4001 4101 4201 4301 4401 4501 4601 4701 4801 4901 5001 5101 5201 5301 5401 5501 5601 5701 5801 5901 6001 6101 6201 6301 6401 6501 6601 6701 6801 6901 7001 7101 7201 7301 7401 7501 7601 7701 7801 7901 8001 8101 8201 8301 8401 8501 8601 8701 8801 8901 9001 9101 9201 9301 9401 9501 9601 9701 9801 9901 1001 1011 1021 1031 1041 1051 1061 1071 1081 1091 1101 1111 1121 1131 1141 1151 1161 1171 1181 1191 1201 1211 1221 1231 1241 1251 1261 1271 1281 1291 1301 1311 1321 1331 1341 1351 1361 1371 1381 1391 1401 1411 1421 1431 1441 1451 1461 1471 1481 1491 1501 1511 1521 1531 1541 1551 1561 1571 1581 1591 1601 1611 1621 1631 1641 1651 1661 1671 1681 1691 1701 1711 1721 1731 1741 1751 1761 1771 1781 1791 1801 1811 1821 1831 1841 1851 1861 1871 1881 1891 1901 1911 1921 1931 1941 1951 1961 1971 1981 1991 2001 2011 2021 2031 2041 2051 2061 2071 2081 2091 2101 2111 2121 2131 2141 2151 2161 2171 2181 2191 2201 2211 2221 2231 2241 2251 2261 2271 2281 2291 2301 2311 2321 2331 2341 2351 2361 2371 2381 2391 2401 2411 2421 2431 2441 2451 2461 2471 2481 2491 2501 2511 2521 2531 2541 2551 2561 2571 2581 2591 2601 2611 2621 2631 2641 2651 2661 2671 2681 2691 2701 2711 2721 2731 2741 2751 2761 2771 2781 2791 2801 2811 2821 2831 2841 2851 2861 2871 2881 2891 2901 2911 2921 2931 2941 2951 2961 2971 2981 2991 3001 3011 3021 3031 3041 3051 3061 3071 3081 3091 3101 3111 3121 3131 3141 3151 3161 3171 3181 3191 3201 3211 3221 3231 3241 3251 3261 3271 3281 3291 3301 3311 3321 3331 3341 3351 3361 3371 3381 3391 3401 3411 3421 3431 3441 3451 3461 3471 3481 3491 3501 3511 3521 3531 3541 3551 3561 3571 3581 3591 3601 3611 3621 3631 3641 3651 3661 3671 3681 3691 3701 3711 3721 3731 3741 3751 3761 3771 3781 3791 3801 3811 3821 3831 3841 3851 3861 3871 3881 3891 3901 3911 3921 3931 3941 3951 3961 3971 3981 3991 4001 4011 4021 4031 4041 4051 4061 4071 4081 4091 4101 4111 4121 4131 4141 4151 4161 4171 4181 4191 4201 4211 4221 4231 4241 4251 4261 4271 4281 4291 4301 4311 4321 4331 4341 4351 4361 4371 4381 4391 4401 4411 4421 4431 4441 4451 4461 4471 4481 4491 4501 4511 4521 4531 4541 4551 4561 4571 4581 4591 4601 4611 4621 4631 4641 4651 4661 4671 4681 4691 4701 4711 4721 4731 4741 4751 4761 4771 4781 4791 4801 4811 4821 4831 4841 4851 4861 4871 4881 4891 4901 4911 4921 4931 4941 4951 4961 4971 4981 4991 5001 5011 5021 5031 5041 5051 5061 5071 5081 5091 5101 5111 5121 5131 5141 5151 5161 5171 5181 5191 5201 5211 5221 5231 5241 5251 5261 5271 5281 5291 5301 5311 5321 5331 5341 5351 5361 5371 5381 5391 5401 5411 5421 5431 5441 5451 5461 5471 5481 5491 5501 5511 5521 5531 5541 5551 5561 5571 5581 5591 5601 5611 5621 5631 5641 5651 5661 5671 5681 5691 5701 5711 5721 5731 5741 5751 5761 5771 5781 5791 5801 5811 5821 5831 5841 5851 5861 5871 5881 5891 5901 5911 5921 5931 5941 5951 5961 5971 5981 5991 6001 6011 6021 6031 6041 6051 6061 6071 6081 6091 6101 6111 6121 6131 6141 6151 6161 6171 6181 6191 6201 6211 6221 6231 6241 6251 6261 6271 6281 6291 6301 6311 6321 6331 6341 6351 6361 6371 6381 6391 6401 6411 6421 6431 6441 6451 6461 6471 6481 6491 6501 6511 6521 6531 6541 6551 6561 6571 6581 6591 6601 6611 6621 6631 6641 6651 6661 6671 6681 6691 6701 6711 6721 6731 6741 6751 6761 6771 6781 6791 6801 6811 6821 6831 6841 6851 6861 6871 6881 6891 6901 6911 6921 6931 6941 6951 6961 6971 6981 6991 7001 7011 7021 7031 7041 7051 7061 7071 7081 7091 7101 7111 7121 7131 7141 7151 7161 7171 7181 7191 7201 7211 7221 7231 7241 7251 7261 7271 7281 7291 7301 7311 7321 7331 7341 7351 7361 7371 7381 7391 7401 7411 7421 7431 7441 7451 7461 7471 7481 7491 7501 7511 7521 7531 7541 7551 7561 7571 7581 7591 7601 7611 7621 7631 7641 7651 7661 7671 7681 7691 7701 7711 7721 7731 7741 7751 7761 7771 7781 7791 7801 7811 7821 7831 7841 7851 7861 7871 7881 7891 7901 7911 7921 7931 7941 7951 7961 7971 7981 7991 8001 8011 8021 8031 8041 8051 8061 8071 8081 8091 8101 8111 8121 8131 8141 8151 8161 8171 8181 8191 8201 8211 8221 8231 8241 8251 8261 8271 8281 8291 830

[illegible]

Year	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	

[illegible][illegible]

1. *Pharmaceutical Innovation and the Role of the State*
 2. *The Impact of Patent Law on Drug Development*
 3. *The Role of Government in Regulating Pharmaceuticals*
 4. *The Impact of Health Insurance on Drug Access*
 5. *The Role of the Pharmaceutical Industry in Public Health*
 6. *The Impact of Globalization on Drug Markets*
 7. *The Role of the Pharmaceutical Industry in Developing Countries*
 8. *The Impact of Intellectual Property on Drug Innovation*
 9. *The Role of the Pharmaceutical Industry in Health Care Reform*
 10. *The Impact of the Pharmaceutical Industry on Public Policy*

For the purpose of the present study, the following hypotheses were formulated:

- (a) The use of a video camera specifically to observe the patient's posture will lead to a decrease in the number of postural errors.
- (b) The use of a video camera specifically to observe the patient's posture will lead to an increase in the number of correct postures.
- (c) The use of a video camera specifically to observe the patient's posture will lead to a decrease in the number of postural errors.
- (d) The use of a video camera specifically to observe the patient's posture will lead to an increase in the number of correct postures.

THE EFFECTS OF THE PRESENCE OF A CRYSTALLINE POLYMER ON THE RATE OF DEGRADATION OF A POLYMER IN A CRYSTALLINE POLYMER

[illegible][illegible]

Journal of Interpersonal Violence 26(10) 1978-1996
© The Author(s) 2011
Reprints and permissions: <http://www.sagepub.com/journalsPermissions.nav>

[illegible][illegible]

Only March 1971	Score 5.2/5.1	DB 1	Length 2441
Best Local Similarity	49.4%	Prod. No. 172	
March 1971	Conservation 4	Mismatches 9	Indels 7
			Gaps 1

140
124 GGGGTTTTCAGAACTTCTTTACCAATGCGAATC 176

RESULT 3	
HMD4 .. XENIA	
11 .. HMD4 XENIA	
12 .. HMD4 XENIA	
13 .. HMD4 XENIA	
14 .. HMD4 XENIA	
15 .. HMD4 XENIA	
16 .. HMD4 XENIA	
17 .. HMD4 XENIA	
18 .. HMD4 XENIA	
19 .. HMD4 XENIA	
20 .. HMD4 XENIA	
21 .. HMD4 XENIA	
22 .. HMD4 XENIA	
23 .. HMD4 XENIA	
24 .. HMD4 XENIA	
25 .. HMD4 XENIA	
26 .. HMD4 XENIA	
27 .. HMD4 XENIA	
28 .. HMD4 XENIA	
29 .. HMD4 XENIA	
30 .. HMD4 XENIA	
31 .. HMD4 XENIA	
32 .. HMD4 XENIA	
33 .. HMD4 XENIA	
34 .. HMD4 XENIA	
35 .. HMD4 XENIA	
36 .. HMD4 XENIA	
37 .. HMD4 XENIA	
38 .. HMD4 XENIA	
39 .. HMD4 XENIA	
40 .. HMD4 XENIA	
41 .. HMD4 XENIA	
42 .. HMD4 XENIA	
43 .. HMD4 XENIA	
44 .. HMD4 XENIA	
45 .. HMD4 XENIA	
46 .. HMD4 XENIA	
47 .. HMD4 XENIA	
48 .. HMD4 XENIA	
49 .. HMD4 XENIA	
50 .. HMD4 XENIA	
51 .. HMD4 XENIA	
52 .. HMD4 XENIA	
53 .. HMD4 XENIA	
54 .. HMD4 XENIA	
55 .. HMD4 XENIA	
56 .. HMD4 XENIA	
57 .. HMD4 XENIA	
58 .. HMD4 XENIA	
59 .. HMD4 XENIA	
60 .. HMD4 XENIA	
61 .. HMD4 XENIA	
62 .. HMD4 XENIA	
63 .. HMD4 XENIA	
64 .. HMD4 XENIA	
65 .. HMD4 XENIA	
66 .. HMD4 XENIA	
67 .. HMD4 XENIA	
68 .. HMD4 XENIA	
69 .. HMD4 XENIA	
70 .. HMD4 XENIA	
71 .. HMD4 XENIA	
72 .. HMD4 XENIA	
73 .. HMD4 XENIA	
74 .. HMD4 XENIA	
75 .. HMD4 XENIA	
76 .. HMD4 XENIA	
77 .. HMD4 XENIA	
78 .. HMD4 XENIA	
79 .. HMD4 XENIA	
80 .. HMD4 XENIA	
81 .. HMD4 XENIA	
82 .. HMD4 XENIA	
83 .. HMD4 XENIA	
84 .. HMD4 XENIA	
85 .. HMD4 XENIA	
86 .. HMD4 XENIA	
87 .. HMD4 XENIA	
88 .. HMD4 XENIA	
89 .. HMD4 XENIA	
90 .. HMD4 XENIA	
91 .. HMD4 XENIA	
92 .. HMD4 XENIA	
93 .. HMD4 XENIA	
94 .. HMD4 XENIA	
95 .. HMD4 XENIA	
96 .. HMD4 XENIA	
97 .. HMD4 XENIA	
98 .. HMD4 XENIA	
99 .. HMD4 XENIA	
100 .. HMD4 XENIA	

BT 01-009-1996 (Ref., 34, last sequence update)
BT 15 JUN 2002 (Ref., 41, last annotation update)
DE Homeobox protein HML-4 (XHL-4).
EN HML-4

Xenopus laevis (African clawed frog),
of Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
of Amphibia; Batrachia; Anura; Mesobatrachia; Pipiloidea; Pipidae;
Xenophora; Xenopus

111
STUDENT FROM N. A.
T. STEPHENSON

RA Papadopoulos M., Kintner C., Jr.:
"Xenopus" listol less related hom
BI chovollon tobria and are in

(c) -1 TISSUE SPECIFICITY: EXPRESSION RESTRICTED TO ANTERIOR EXTRINSIC DERIVATIVES, NAMELY THE VENTRAL FOREBRAIN, THE CRANIAL NERVE

1 SIMILARITY: BELONGS TO THE DISTAL-LESS HOMOPROX FAMILY.
2 PROTEINS.
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836

This SWISS PREPRINT is copyright © 1997 by the European Bioinformatics Institute and the EMBL outstation. It is produced through a collaboration between the two institutions. There are no restrictions on its use by non-profit institutions or as a source of information.

the mail is located and this statement is not removed. Users by and for commercial entities are required to have a statement of their business and to have a statement of record in order to be considered for service (see 47 CFR 1.1200 (b)(3)).

14 "Characterization of hematopoietic intercellular protein tyrosine
15 phosphatases: description of a phosphatase containing an SH2 domain
16 and another on tyrosine in fibronectin, glutamic acid, serine, and
17 tyrosine phosphorylation sequences."

18 M. J. Cantley, B. J. Goldstein, J. Schless, and J. Schless (1992).

19 1. CATALYTIC ACTIVITY: protein tyrosine phosphate + H(2)O = protein
20 tyrosine + phosphate.
21 SUBSTRATE SPECIFICITY: cytoplasmic,
22 TISSUE SPECIFICITY: SKIN, THYMUS, LYMPH NODE, AND BONE MARROW.
23 SIMILARITY: BELONGS TO THE NON RECEPTOR CLASS OF THE PROTEIN-
24 TYROSINE PHOSPHATASE FAMILY.

25 This SwissProt entry is copyright. It is produced through a collaboration
26 between the Swiss Institute of Bioinformatics and the EMBL outstation.
27 The European Bioinformatics Institute, there are no restrictions on its
28 use by non-profit institutions as long as its content is in no way
29 modified and this statement is not removed. Usage by and for commercial
30 entities requires a license agreement (See <http://www.ebi.ac.uk/infocentre/>
31 or send an email to license@ebi.ac.uk).

32 PROSITE: PS00044 (1.1)

33 PROSITE: PS00044 (1.1)

34 PROSITE: PS00044 (1.1)

35 PROSITE: PS00044 (1.1)

36 PROSITE: PS00044 (1.1)

37 PROSITE: PS00044 (1.1)

38 PROSITE: PS00044 (1.1)

39 PROSITE: PS00044 (1.1)

40 PROSITE: PS00044 (1.1)

41 PROSITE: PS00044 (1.1)

42 PROSITE: PS00044 (1.1)

43 PROSITE: PS00044 (1.1)

44 PROSITE: PS00044 (1.1)

45 PROSITE: PS00044 (1.1)

46 PROSITE: PS00044 (1.1)

47 PROSITE: PS00044 (1.1)

48 PROSITE: PS00044 (1.1)

49 PROSITE: PS00044 (1.1)

50 PROSITE: PS00044 (1.1)

51 PROSITE: PS00044 (1.1)

52 PROSITE: PS00044 (1.1)

53 PROSITE: PS00044 (1.1)

54 PROSITE: PS00044 (1.1)

55 PROSITE: PS00044 (1.1)

56 PROSITE: PS00044 (1.1)

57 PROSITE: PS00044 (1.1)

58 PROSITE: PS00044 (1.1)

59 PROSITE: PS00044 (1.1)

60 PROSITE: PS00044 (1.1)

61 PROSITE: PS00044 (1.1)

62 PROSITE: PS00044 (1.1)

63 PROSITE: PS00044 (1.1)

64 PROSITE: PS00044 (1.1)

65 PROSITE: PS00044 (1.1)

66 PROSITE: PS00044 (1.1)

67 PROSITE: PS00044 (1.1)

68 PROSITE: PS00044 (1.1)

CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.ebi.ac.uk/infocentre/>
CC or send an email to license@ebi.ac.uk).

69 EMBL: X82896; CAA63489.1
70 DR MIM: 300060
71 SPQUENCE 105 AA: 11232 MW: 11665766.279646 CRR64

Query Match 29.1% Score 469 DB 105

Best Local Similarity 38.5% Pred. No. 52

Matches 10: Conservative 5: Mismatches 1: Indels 0: Gaps 0:

Db 2 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See <http://www.ebi.ac.uk/infocentre/>
CC or send an email to license@ebi.ac.uk).

72 EMBL: X82896; CAA63489.1
73 DR MIM: 300060
74 SPQUENCE 105 AA: 11232 MW: 11665766.279646 CRR64

Query Match 29.1% Score 469 DB 105

Best Local Similarity 38.5% Pred. No. 52

Matches 10: Conservative 5: Mismatches 1: Indels 0: Gaps 0:

Db 2 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

37 TROVACAT:PELVICAVINAAAHINCP 62

[illegible][illegible]



[illegible][illegible]

